SEALAPEX
K972369 · Sybron Dental Specialties, Inc. · KIF · Aug 15, 1997 · Dental
Device Facts
| Record ID | K972369 |
| Device Name | SEALAPEX |
| Applicant | Sybron Dental Specialties, Inc. |
| Product Code | KIF · Dental |
| Decision Date | Aug 15, 1997 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 872.3820 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
Kerr Modified Sealapex Root Canal Sealer is a two- paste, non-eugenol, radiopaque, calcium hydroxide polymeric resin root canal filling material. It is intended for use as a root canal sealer to be used in conjunction with gutta percha or silver endodontic points.
Device Story
Kerr Modified Sealapex is a two-paste, calcium hydroxide-based root canal sealer; used by dentists during endodontic procedures. Device functions as a filling material to seal root canals when used with gutta percha or silver points. Modifications include replacing poly(methylene methyl salicylate) resin with NPG-TMP salicylate to eliminate formaldehyde usage and adding bismuth trioxide to increase radiopacity. Material is applied by clinician to the root canal space; provides biocompatible seal; stimulates hard tissue formation in periapical area and along canal walls. Benefits include improved manufacturing safety and enhanced radiographic visibility for clinical assessment of seal integrity.
Clinical Evidence
No clinical trials performed. Evidence consists of animal histopathology studies demonstrating biocompatibility and hard tissue stimulation, and bench testing comparing the modified formulation to predicate devices per ISO 6876 standards for dental root canal sealing materials.
Technological Characteristics
Two-paste, non-eugenol, calcium hydroxide polymeric resin system. Key components: NPG-TMP salicylate resin, bismuth trioxide (radiopaquing agent). Form factor: dual-paste delivery. Sterilization: not specified. Connectivity: none. Software: none.
Indications for Use
Indicated for use as a root canal sealer in conjunction with gutta percha or silver endodontic points for dental patients requiring root canal therapy.
Regulatory Classification
Identification
A root canal filling resin is a device composed of material, such as methylmethacrylate, intended for use during endodontic therapy to fill the root canal of a tooth.
Predicate Devices
- Sealapex (K841910)
- Sealapex (K944480)
Reference Devices
- Life Cavity Base/Liner (K961708)
- Procosol
- Grossman's Sealer
- Wach's Paste
- Diaket
- AH-26
Related Devices
- K152959 — Sealapex tubes, Sealapex bulk package, Sealapex Xpress dual-barrel syringes · Sybron Dental Specialties · Apr 14, 2016
- K212563 — CalApex Calplus, Cerafill RCS, Endoseal, Nanoseal S, Zical Ultra Paste, Zical Ultra Powder/Liquid · Prevest Denpro Limited · May 23, 2022
- K042769 — ADSEAL ROOT CANAL SEALER · Meta Biomed Co., Ltd. · Nov 24, 2004
- K202281 — EDS Bioceramic Sealer (Bioseal) · Essential Dental Systems · Feb 12, 2021
- K252890 — ZenSeal Pro · Kerr Corporation · Jan 7, 2026
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows a sequence of handwritten characters. The characters are 'K', '9', '7', '2', '3', '6', and '9'. The characters are written in black ink on a white background.
Page 1 of 2
.
# 510 ( k ) Summary
## Statement of Safety an Effectiveness
## Kerr Modified Sealapex Root Canal Sealer
#### BACKGROUND
Sealapex is a root canal sealing material which has been used successfully by the dental profession since 1984. The original Sealapex formulation received market clearance from the Food and Drug Administration in July of 1984 ( 510 ( k ) Reference Number K841910 ).Another 510 ( k ) application was submitted in September, 1994 for minor formulation changes to extend the working time ( 510 ( k ) Reference Number K944480 ). This submission addresses two anticipated formulation modifications which will, when implemented, make the manufacturing process for synthesizing one of the polymeric resins safer to the employees, and increase the radiopacity by fifty per cent.
Current Sealapex formulations utilize Poly(methylene methyl salicylate) resin in the catalyst paste component. It is synthesized in-house using formaldehyde as one of the reactants. Formaldehyde is considered to be carcinogenic and presents a serious hazard in the workplace. If Neopentyl glycol disalicylate/ trimethylol propane trisalicylate ( NPG-TMP salicylate ) resin is substituted for the current resin, the use of formaldehyde is eliminated. The second modification consists of the addition of bismuth trioxide to the catalyst component to increase the radiopacity of the mixed sealant.
#### Modified Sealapex
The two formulation changes described above do not alter the safety and efficacy of the product to the extent that the new formulation is not significantly equivalent to products currently on the market and under the jurisdiction of FDA. This is demonstrated below:
Change Number 1: Substitution of poly(methylene methyl salicylate) resin with NPG-TMP Salicylate resin. NPG-TMP Salicylate has been used successfully and safely since 1996 in Kerr's Life Cavity Base/Liner ( 510 ( k ) Reference Number K961708 ). And, in fact, that resin change was made for exactly the same reasons described in this submission and was based on extensive animal histopathology studies which demonstrated both the biocompatibility of the resin and the ability of the calcium hydroxide ingredient to stimulate the formation of hard tissue both in the periapical area and along the canal walls as well.
Change Number 2: The addition of bismuth trioxide to increase the radiopacity of the set sealant. Bismuth trioxide has been used previously in root canal sealers. Procosol. Grossman's Sealer, Wach's Paste, Diaket and AH-26 all use bismuth compounds as radiopaquing agents. In the case of AH-26, it has 60 % by weight bismuth trioxide All of these products are currently on the market under the jurisdiction of FDA.
A table of comparative ingredient lists for the modified Sealapex formulation along with predicate device compositions, where known is included elsewhere in this submission in order to contrast and compare the various devices.
{1}------------------------------------------------
Page 2 of 2
### Safety
The safety of the modified Sealapex formulation has been demonstrated in extensive animal histopathology studies. Copies of reports of these studies are included elsewhere in this submission.
#### Efficacy
The effectiveness of the modified Sealapex formulation has been demonstrated by comparison testing of several predicate devices to the requirements of ISO International Standard 6876 for Dental root canal sealing materials. A copy of this standard as well as a table of comparative results can be found elsewhere in this submission.
{2}------------------------------------------------
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 1 5 1997
Mr. William R. Pike Regulatory Affairs Specialist Sybron Dental Specialities, Incorporated 2717 W. Collins Avenue -Orange, California 92667
Re: K972369 Trade Name: Sealapex Regulatory Class: II Product Code: KIF June 6, 1997 Dated: Received: June 25, 1997
Dear Mr. Pike:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, qood manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ರ್ಥ substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Requlation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note:
this response to your premarket notification submission does not affect any obligation you might have under sections 531
{3}------------------------------------------------
Page 2 - Mr. Pike
through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification focument device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Timothy A. Ulatowski
Director Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510 ( k ) Number :
Device Name : Kerr Modified Sealapex Root Canal Sealer
Indications For Use : Kerr Modified Sealapex Root Canal Sealer is a two- paste, non-eugenol, radiopaque, calcium hydroxide polymeric resin root canal filling material. It is intended for use as a root canal sealer to be used in conjunction with gutta percha or silver endodontic points.
Susan Runsey
(Division Sign-Off)
Division of Dental, Infection Control, and General Hospital Devices 510(k) Number _ Jeg 72369
Prescription Use
(Per 21 CFR 801.109)